Chardan initiated coverage of Climb Bio (CLYM) with a Buy rating and $22 price target The firm says the company is advancing two “differentiated” monoclonal antibodies targeting “validated but improvable” mechanisms in B cell-mediated autoimmune disease. Climb has five clinical readouts in 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: